Research!America unveils 2016 policy wish list

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

RESEARCH!AMERICA unveiled its policy wish list for 2016, urging Congress to take action on several research priorities.

“Congress should act this year to sustain robust funding for federal health agencies, advance medical innovation and mental health legislation, and permanently repeal the medical device tax,” they said in a statement.

The advocacy group said that additional funds for NIH and FDA will support innovative projects including precision medicine, Alzheimer’s research and efforts to combat antimicrobial resistance, however “the budget for the Agency for Healthcare Research and Quality was cut by eight percent in the spending bill, further limiting the agency’s ability to address costly errors and inefficiencies in health care delivery. Sustainable and predictable investments for AHRQ and other health agencies are critical to accelerating medical progress.”

The group also called attention to a bill being drafted by a Senate committee, called the Innovations for Healthier Americans Initiative, which is companion legislation for the 21st Century Cures bill, which passed in the House last year.

“Research!America urges Senate action early this year on legislation that responsibly modernizes regulatory pathways for new drugs and medical devices, and includes mandatory funding for the NIH and FDA. The goal must be to enact meaningful legislation this year.”

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings. 
At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 
In 2026, more than 900 million people are estimated to be regularly using generative artificial intelligence—computer systems capable of creating human-like text, images, audio, video, and other original content. AI is becoming integrated into nearly every aspect of daily life. Health care is no exception. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login